Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Sidec Technologies in the issue of new shares
Mandate

Vinge represents Sidec Technologies in the issue of new shares

May 09, 2007

Vinge is representing Sidec Technologies, in conjunction with the investments by Industrifonden, Investor and Earlybird of Germany in the company. A capital infusion of SEK 68.5 million means that Sidec can implement its planned efforts on the European and American markets. The company, which was established in 2000, is a spin-off from research at the Karolinska Institute, and is engaged in technology developed for studies of protein.
 
Partner Johan Winnerbald and associate Anna Berntsson represent Sidec Technologies AB.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025